Interesting article - response to aricle in New York Times
Developing New Antibiotics
June 7, 2013
To the Editor:
In “Pressure Grows to Create Drugs for ‘Superbugs’ ” (front page, June 3), Dr. Janet Woodcock of the Food and Drug Administration notes that the antibiotics pipeline is so thin that we face “a huge crisis worldwide.”
Recent legislation providing incentives for the development of antibiotics is an important step but will likely have limited impact. The unmentioned and perhaps larger issue is that many, including physicians, insurers and pharmacists, expect antibiotics, which may cure us of a potentially fatal infection, to be virtually free. In contrast, treatments for cancer, which may extend life for a few months but not cure patients, commonly command prices of tens of thousands of dollars.
Critics of incentives to antibiotic developers often cite safety concerns and the risk that rapid development pathways may result in the overuse of new treatments. This misses the point. In fact, it is the absence of market incentives that drives the abandonment of antibiotic development, the overuse of cheap generics and the consequent resistance crisis we face today.
San Diego, June 6, 2013
The writer is president and chief executive of Trius Therapeutics, a biopharmaceutical company.
It should be self evident that with the limited attention placed on antibiotic development, tedizoliod with solid
results to present and efficacy that beats "the competition", is truely a gem in drugs for superbugs. Further testing will most positively result in it's clearance for more life threatening infections.